Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Weekly RM-718 shows double-digit BMI reduction in small hypothalamic obesity trial
Rhythm Pharmaceuticals reports an 11.6% BMI reduction with weekly RM-718 as it expands a rare obesity franchise built around three treatments.
Could monthly treatment replace burdensome peanut allergy dosing? Aravax may soon have an answer
Aravax gains FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach and preparations for a possible Phase 3 program advance.
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.
Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps
Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Lantern Pharma just separated its AI platform, but will Open Medicine AI unlock real shareholder value?
Lantern Pharma has established Open Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform, moving a previously planned separation into an active corporate structure. The decision could give the artificial intelligence business greater strategic focus and access to specialized funding, but ownership, intellectual property, customer revenue and future listing arrangements will determine whether the move creates measurable value for Lantern Pharma shareholders.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
Can Diakonos make personalized melanoma cell therapy work without toxic conditioning?
Diakonos begins DOC1021 melanoma dosing as its outpatient cell therapy challenges intensive treatment and tests patient-specific manufacturing.
EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout
EyePoint completes Phase 3 DME enrollment as DURAVYU targets six-month dosing, with wet AMD data due in August and DME results in late 2027.
Moleculin’s $9.3m raise adds 49.5m potential shares after MIRACLE update
Moleculin’s 37% MIRACLE remission signal is followed by a $9.3 million offering, heavy warrant dilution and a 59% stock drop.